Ozempic and every other GLP-1 drug sold in the United States must now carry a warning about a rare eye condition that can cause sudden, permanent vision loss, the Food and Drug Administration announced Monday, Nov. 9. The condition, called nonarteritic anterior ischemic optic neuropathy, or NAION, cuts off blood flow to the optic nerve […]
The postOzempic’s silent eye threat FDA now wants you to knowappeared first onRolling Out.



